Check out our most popular compounded medications! Get Started
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
Prepared to a prescriber's order for one patient. Not FDA-approved.
This is a compounded topical gel containing timolol maleate, prepared to a prescriber's order for one patient. Compounded preparations are not FDA-approved.
These listings cover every salt or ester form of each drug in the FDA National Drug Code Directory.
FDA-approved products containing timolol are listed in solution and tablet forms. No timolol product of any kind is listed in gel form.
Gel bases can be aqueous or nonaqueous, and USP <795> classifies the preparation by its water activity. Aqueous preparations carry shorter default beyond-use dates than nonaqueous ones. The date printed on the label is the one to follow.
Timolol is a nonselective beta-blocker; compounding pharmacies prepare it as preservative-free eye drops and topical skin preparations by prescription.
Timolol maleate is a nonselective beta1 and beta2 adrenergic blocker without significant intrinsic sympathomimetic or membrane-stabilizing activity. In the eye it lowers intraocular pressure, mainly by reducing production of aqueous humor. Preservative-free Timoptic in Ocudose (Nordic Pharma) is FDA-approved to treat elevated intraocular pressure in ocular hypertension or open-angle glaucoma, including for patients sensitive to the preservative benzalkonium chloride; other manufactured eye drops include gel-forming solutions and combinations with dorzolamide or brimonidine. Timolol tablets (for example Rising Pharma) are approved for hypertension, for reducing cardiovascular death and reinfarction after a heart attack, and for migraine prevention. Prescribers may order timolol compounded when they need a strength, preservative-free vehicle or topical skin form that is not manufactured. Compounded preparations are not FDA-approved and require a prescription.
The eye drop label has no boxed warning, but drops reach the bloodstream, and severe breathing and heart reactions, including deaths from bronchospasm in people with asthma and rarely from heart failure, have been reported. Do not use timolol if you have current or past asthma, severe COPD, a slow heart rate, second or third degree heart block, overt heart failure or cardiogenic shock. It can hide signs of low blood sugar and an overactive thyroid. Tell your prescriber if you take an oral beta-blocker, a calcium channel blocker, digoxin, quinidine or an SSRI, or have myasthenia gravis. The label advises use in pregnancy only if benefit justifies risk and notes timolol enters breast milk; LactMed says eye use poses little risk to a nursing infant and that pressing on the tear duct after drops reduces absorption. For wheezing or a slow pulse, talk to your prescriber or pharmacist.
Topically, timolol lowers elevated and normal intraocular pressure, predominantly by reducing aqueous formation; onset is usually within half an hour, with maximum effect at one to two hours lasting up to 24 hours (Ocudose label). StatPearls reports systemic bioavailability of ophthalmic timolol of 60 to 78 percent, with peak plasma levels within 15 minutes. Orally (timolol tablet label), about 90 percent is absorbed with roughly 50 percent first-pass metabolism, peak levels occur at one to two hours, plasma half-life is about 4 hours, protein binding is under 10 percent by equilibrium dialysis, and the drug and metabolites are renally excreted; StatPearls names CYP2D6 as the main metabolic enzyme. Labeled indications: Timoptic in Ocudose for ocular hypertension and open-angle glaucoma (pediatric efficacy established from age 2); timolol tablets for hypertension, post-MI secondary prevention and migraine prophylaxis. StatPearls lists topical timolol for thin, superficial infantile hemangiomas as an off-label use and notes that the American Academy of Pediatrics allows clinicians to prescribe it off-label for this purpose; it is not an FDA-approved indication. Dosing is per prescriber. Monitor intraocular pressure, heart rate, blood pressure and respiratory symptoms; CYP2D6 inhibitors such as quinidine and SSRIs can potentiate systemic beta-blockade. Avoid abrupt withdrawal of systemic beta-blockers in ischemic heart disease. Timolol is not a controlled substance.
Wash your hands. Apply the amount on your label to clean, dry skin and spread it in a thin layer. For a metered pump, your label states the number of presses. For a dosing syringe, push the plunger to the mark. Let the gel dry before covering with clothing. Wash your hands afterward and keep the site from touching other people until it has dried. Do not apply to broken skin unless told to.
A gel can have a nonaqueous or a water-based base, and USP <795> sets its default beyond-use date by water content, not by the word gel. A nonaqueous gel usually carries a beyond-use date of up to 180 days at room temperature or refrigerated. A water-based gel carries up to 35 days with a preservative, or 14 days refrigerated without one. Your label states which applies. Keep the container closed, away from heat and open flame if it contains alcohol, out of reach of children, and discard after the beyond-use date on your label.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice. Discuss your situation with a licensed healthcare provider.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
Apply topically to affected area(s)
